Co-Authors
This is a "connection" page, showing publications co-authored by Massimo Puoti and Marco Massari.
Connection Strength
0.330
-
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One. 2017; 12(2):e0172159.
Score: 0.177
-
Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS One. 2021; 16(2):e0247275.
Score: 0.058
-
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? Liver Int. 2018 12; 38(12):2190-2198.
Score: 0.049
-
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology. 2017 12; 66(6):1814-1825.
Score: 0.046